Publications:248
Samuel Waxman, MD
About Me
N/A
Language
English
Position
PROFESSOR EMERITUS | Medicine, Hematology and Medical Oncology, PROFESSOR EMERITUS | Oncological Sciences
Publications
Selected Publications
- Optimization of 4-Aniline Substituted Pyrido[3,2-d]pyrimidine Derivatives as Pim/Mnk Dual Inhibitors with Antileukemia Activity. Kun Xing, Shujun Li, Shuwei Zuo, Huimin Zhang, Fuyao Zhang, Jinghuan Li, Jiachen Wen, Dan Liu, Samuel Waxman, Yongkui Jing, Min Huang, Jingyi Zhang, Linxiang Zhao. Journal of Medicinal Chemistry
- Overcoming venetoclax resistance through heme-mediated NOXA/cyclin D1/Mcl-1 axis with a novel artemisinin conjugate. Jingyi Zhang, Zhenwei Zhang, Jinghua Liu, Shenglin Luan, Jiqiang Qu, Zi Wu, Yafei Kuang, Ping Gong, Yu Bao, Yuetong Wang, Xiaojing Yan, Samuel Waxman, Linxiang Zhao, Yongkui Jing. Blood advances
- Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality. Ying Li, Xiaoxiao Gao, Huimin Zhang, Yang Qiu, Meng Chai, Jinghua Liu, Xiaojing Yan, Samuel Waxman, Jingyi Zhang, Yongkui Jing. Phytomedicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Waxman has not yet completed reporting of industry relationships or has no industry relationships to report.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.